cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...
Autism Compound, KM-391 Showing Significant Improvements On Key Parameters In Animal Studies
 
 
Press Release Audio 2-16-2010
 
 
Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Req by FDA
Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain
Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes
Cellceutix Responds to Public Support by Expediting Autism Studies - Completes Two Required Safety P
Cellceutix CFO Discusses Autism Drug - Kevetrin and Company Progressions with CEOCFO Interviews and
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support; Company Continues to Advance Kevetrin
Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer C
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound Pfizer and Novartis
Cellceutix Presents Poster Session at AACR Important New Data on Kevetrin in Resistant Lung Can
Cellceutix at AACR
Cellceutix Ceo Appears On Stu Taylor On Business - Cancer And Autism Compounds Are Discussed
Cellceutix Announces Positive Results With Autism Compound
Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech
Cellceutix Abstract Accepted by AACR
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation
Cellceutix Poster Presented at American Association for Cancer Research
Cellceutix Compound Shows Significant Effect On Psoriasis
Kevetrin" Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer
Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties
Cellceutix Signs Manufacturing Agreement for Kevetrin Active Pharmaceutical Ingredient
Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board
CTIX Announces Lung Cancer Animal Model Testing Results with Kevetrin
Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010
Cellceutix cancer compound: Crunching the numbers